Cargando…
Outcome Measures for Disease-Modifying Trials in Parkinson’s Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative
BACKGROUND: Multi-arm, multi-stage (MAMS) platform trials can accelerate the identification of disease-modifying treatments for Parkinson’s disease (PD) but there is no current consensus on the optimal outcome measures (OM) for this approach. OBJECTIVE: To provide an up-to-date inventory of OM for d...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578294/ https://www.ncbi.nlm.nih.gov/pubmed/37545260 http://dx.doi.org/10.3233/JPD-230051 |
_version_ | 1785121491287801856 |
---|---|
author | Gonzalez-Robles, Cristina Weil, Rimona S. van Wamelen, Daniel Bartlett, Michèle Burnell, Matthew Clarke, Caroline S. Hu, Michele T. Huxford, Brook Jha, Ashwani Lambert, Christian Lawton, Michael Mills, Georgia Noyce, Alastair Piccini, Paola Pushparatnam, Kuhan Rochester, Lynn Siu, Carroll Williams-Gray, Caroline H. Zeissler, Marie-Louise Zetterberg, Henrik Carroll, Camille B. Foltynie, Thomas Schrag, Anette |
author_facet | Gonzalez-Robles, Cristina Weil, Rimona S. van Wamelen, Daniel Bartlett, Michèle Burnell, Matthew Clarke, Caroline S. Hu, Michele T. Huxford, Brook Jha, Ashwani Lambert, Christian Lawton, Michael Mills, Georgia Noyce, Alastair Piccini, Paola Pushparatnam, Kuhan Rochester, Lynn Siu, Carroll Williams-Gray, Caroline H. Zeissler, Marie-Louise Zetterberg, Henrik Carroll, Camille B. Foltynie, Thomas Schrag, Anette |
author_sort | Gonzalez-Robles, Cristina |
collection | PubMed |
description | BACKGROUND: Multi-arm, multi-stage (MAMS) platform trials can accelerate the identification of disease-modifying treatments for Parkinson’s disease (PD) but there is no current consensus on the optimal outcome measures (OM) for this approach. OBJECTIVE: To provide an up-to-date inventory of OM for disease-modifying PD trials, and a framework for future selection of OM for such trials. METHODS: As part of the Edmond J Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT-PD) initiative, an expert group with Patient and Public Involvement and Engagement (PPIE) representatives’ input reviewed and evaluated available evidence on OM for potential use in trials to delay progression of PD. Each OM was ranked based on aspects such as validity, sensitivity to change, participant burden and practicality for a multi-site trial. Review of evidence and expert opinion led to the present inventory. RESULTS: An extensive inventory of OM was created, divided into: general, motor and non-motor scales, diaries and fluctuation questionnaires, cognitive, disability and health-related quality of life, capability, quantitative motor, wearable and digital, combined, resource use, imaging and wet biomarkers, and milestone-based. A framework for evaluation of OM is presented to update the inventory in the future. PPIE input highlighted the need for OM which reflect their experience of disease progression and are applicable to diverse populations and disease stages. CONCLUSION: We present a range of OM, classified according to a transparent framework, to aid selection of OM for disease-modifying PD trials, whilst allowing for inclusion or re-classification of relevant OM as new evidence emerges. |
format | Online Article Text |
id | pubmed-10578294 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-105782942023-10-17 Outcome Measures for Disease-Modifying Trials in Parkinson’s Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative Gonzalez-Robles, Cristina Weil, Rimona S. van Wamelen, Daniel Bartlett, Michèle Burnell, Matthew Clarke, Caroline S. Hu, Michele T. Huxford, Brook Jha, Ashwani Lambert, Christian Lawton, Michael Mills, Georgia Noyce, Alastair Piccini, Paola Pushparatnam, Kuhan Rochester, Lynn Siu, Carroll Williams-Gray, Caroline H. Zeissler, Marie-Louise Zetterberg, Henrik Carroll, Camille B. Foltynie, Thomas Schrag, Anette J Parkinsons Dis Consensus Paper BACKGROUND: Multi-arm, multi-stage (MAMS) platform trials can accelerate the identification of disease-modifying treatments for Parkinson’s disease (PD) but there is no current consensus on the optimal outcome measures (OM) for this approach. OBJECTIVE: To provide an up-to-date inventory of OM for disease-modifying PD trials, and a framework for future selection of OM for such trials. METHODS: As part of the Edmond J Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT-PD) initiative, an expert group with Patient and Public Involvement and Engagement (PPIE) representatives’ input reviewed and evaluated available evidence on OM for potential use in trials to delay progression of PD. Each OM was ranked based on aspects such as validity, sensitivity to change, participant burden and practicality for a multi-site trial. Review of evidence and expert opinion led to the present inventory. RESULTS: An extensive inventory of OM was created, divided into: general, motor and non-motor scales, diaries and fluctuation questionnaires, cognitive, disability and health-related quality of life, capability, quantitative motor, wearable and digital, combined, resource use, imaging and wet biomarkers, and milestone-based. A framework for evaluation of OM is presented to update the inventory in the future. PPIE input highlighted the need for OM which reflect their experience of disease progression and are applicable to diverse populations and disease stages. CONCLUSION: We present a range of OM, classified according to a transparent framework, to aid selection of OM for disease-modifying PD trials, whilst allowing for inclusion or re-classification of relevant OM as new evidence emerges. IOS Press 2023-09-08 /pmc/articles/PMC10578294/ /pubmed/37545260 http://dx.doi.org/10.3233/JPD-230051 Text en © 2023 – The authors. Published by IOS Press https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) License (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Consensus Paper Gonzalez-Robles, Cristina Weil, Rimona S. van Wamelen, Daniel Bartlett, Michèle Burnell, Matthew Clarke, Caroline S. Hu, Michele T. Huxford, Brook Jha, Ashwani Lambert, Christian Lawton, Michael Mills, Georgia Noyce, Alastair Piccini, Paola Pushparatnam, Kuhan Rochester, Lynn Siu, Carroll Williams-Gray, Caroline H. Zeissler, Marie-Louise Zetterberg, Henrik Carroll, Camille B. Foltynie, Thomas Schrag, Anette Outcome Measures for Disease-Modifying Trials in Parkinson’s Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative |
title | Outcome Measures for Disease-Modifying Trials in Parkinson’s Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative |
title_full | Outcome Measures for Disease-Modifying Trials in Parkinson’s Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative |
title_fullStr | Outcome Measures for Disease-Modifying Trials in Parkinson’s Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative |
title_full_unstemmed | Outcome Measures for Disease-Modifying Trials in Parkinson’s Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative |
title_short | Outcome Measures for Disease-Modifying Trials in Parkinson’s Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative |
title_sort | outcome measures for disease-modifying trials in parkinson’s disease: consensus paper by the ejs act-pd multi-arm multi-stage trial initiative |
topic | Consensus Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578294/ https://www.ncbi.nlm.nih.gov/pubmed/37545260 http://dx.doi.org/10.3233/JPD-230051 |
work_keys_str_mv | AT gonzalezroblescristina outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT weilrimonas outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT vanwamelendaniel outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT bartlettmichele outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT burnellmatthew outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT clarkecarolines outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT humichelet outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT huxfordbrook outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT jhaashwani outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT lambertchristian outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT lawtonmichael outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT millsgeorgia outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT noycealastair outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT piccinipaola outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT pushparatnamkuhan outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT rochesterlynn outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT siucarroll outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT williamsgraycarolineh outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT zeisslermarielouise outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT zetterberghenrik outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT carrollcamilleb outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT foltyniethomas outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT schraganette outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative AT outcomemeasuresfordiseasemodifyingtrialsinparkinsonsdiseaseconsensuspaperbytheejsactpdmultiarmmultistagetrialinitiative |